Key result
Cancer therapeutics, including anthracyclines, trastuzumab, and tyrosine kinase inhibitors, are associated with significant cardiotoxicity, necessitating early detection through biomarkers and imaging.
Population
Cancer patients and survivors receiving potentially cardiotoxic medical therapies
Design
Review
Authors
Loading...
Heightens cardiotoxicity vigilance during cancer therapy; leaves open optimal biomarker and imaging protocols for validation.
This review highlights the growing concern of chemotherapy-induced cardiotoxicity and the need for early screening using serological markers and novel cardiac imaging.
Sheppard et al. (2013) conducted a review in Chemotherapy-induced cardiotoxicity in cancer patients. Cancer therapeutics (Anthracyclines, Monoclonal antibodies, Tyrosine kinase inhibitors) was evaluated. Cancer therapeutics, including anthracyclines, trastuzumab, and tyrosine kinase inhibitors, are associated with significant cardiotoxicity, necessitating early detection through biomarkers and imaging.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: